Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796614 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 231
- Enrollment target
NCT00796614 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 231 participants.
The verdict
NCT00796614, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 231 participants
- Enrollment target
Study Summary
Aim of this study is to evaluate the efficacy and safety of a range of doses of tamsulosin hydrochloride as treatment in children with an elevated detrusor leak point pressure associated with a known neurological deficit
Interventions
- DRUG Placebo
- DRUG tamsulosin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00796614
The ClinicalTrials.gov registry entry for NCT00796614 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00796614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00796614 about?
NCT00796614 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder". Aim of this study is to evaluate the efficacy and safety of a range of doses of tamsulosin hydrochloride as treatment in children with an elevated detrusor leak point pressure associated with a known neurological deficit
What is the current status of trial NCT00796614?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 231 participants. The study started on 2008-01. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00796614?
The interventions under investigation include: Placebo (DRUG), tamsulosin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00796614?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.